Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Novel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease.

Lanthier C, Payan H, Liparulo I, Hatat B, Lecoutey C, Since M, Davis A, Bergamini C, Claeysen S, Dallemagne P, Bolognesi ML, Rochais C.

Eur J Med Chem. 2019 Aug 6;182:111596. doi: 10.1016/j.ejmech.2019.111596. [Epub ahead of print]


Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease.

Toublet FX, Lecoutey C, Lalut J, Hatat B, Davis A, Since M, Corvaisier S, Freret T, Sopkova de Oliveira Santos J, Claeysen S, Boulouard M, Dallemagne P, Rochais C.

Molecules. 2019 Jul 31;24(15). pii: E2786. doi: 10.3390/molecules24152786.


Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase.

Lalut J, Santoni G, Karila D, Lecoutey C, Davis A, Nachon F, Silman I, Sussman J, Weik M, Maurice T, Dallemagne P, Rochais C.

Eur J Med Chem. 2019 Jan 15;162:234-248. doi: 10.1016/j.ejmech.2018.10.064. Epub 2018 Nov 8.


Benzylphenylpyrrolizinones with Anti-amyloid and Radical Scavenging Effects, Potentially Useful in Alzheimer's Disease Treatment.

Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopková-de Oliveira Santos J, Cresteil T, Malzert-Fréon A, Rochais C, Dallemagne P.

ChemMedChem. 2017 Jun 21;12(12):913-916. doi: 10.1002/cmdc.201700102. Epub 2017 Apr 12.


Synthesis and evaluation of novel serotonin 4 receptor radiotracers for single photon emission computed tomography.

Lalut J, Tournier BB, Cailly T, Lecoutey C, Corvaisier S, Davis A, Ballandonne C, Since M, Millet P, Fabis F, Dallemagne P, Rochais C.

Eur J Med Chem. 2016 Jun 30;116:90-101. doi: 10.1016/j.ejmech.2016.03.059. Epub 2016 Mar 25.


Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.

Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-Fréon A, Rochais C, Dallemagne P.

Eur J Med Chem. 2016 May 23;114:365-79. doi: 10.1016/j.ejmech.2016.03.023. Epub 2016 Mar 12.


Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.

Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D, Dubost E, Genest D, Yahiaoui S, Freret T, Bouet V, Dauphin F, Sopkova de Oliveira Santos J, Ballandonne C, Corvaisier S, Malzert-Fréon A, Legay R, Boulouard M, Claeysen S, Dallemagne P.

J Med Chem. 2015 Apr 9;58(7):3172-87. doi: 10.1021/acs.jmedchem.5b00115. Epub 2015 Mar 31.


Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.

Lecoutey C, Hedou D, Freret T, Giannoni P, Gaven F, Since M, Bouet V, Ballandonne C, Corvaisier S, Malzert Fréon A, Mignani S, Cresteil T, Boulouard M, Claeysen S, Rochais C, Dallemagne P.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):E3825-30. doi: 10.1073/pnas.1410315111. Epub 2014 Aug 25.

Supplemental Content

Loading ...
Support Center